Dermata Therapeutics Inc (DRMA)

[The Night Stalker]

nailed bottom, want to see volume pick up from here, consider offerings as a way to buy cheap shares

[The Night Stalker]

its starting, can see 2.00 today or by friday

[The Night Stalker]

the run to 3.84 was for good reason ,, want to see volume pick up, up from here its peers did big pops. this will to in coming weeks with this rare tiny market cap

[sal32647]

I bought more,I'm loaded

[The Night Stalker]

was a good double up, with EPS at 2.37 hence last pop to 3.84 on that PR. selling on offering is dumb in bigboard biotech, double up and wait ,,,

[The Night Stalker]

doubled up here, june is when phase 3 starts. will get that big pop in coming weeks

[The Night Stalker]

wired money to average all the way down

[The Night Stalker]

6 red days now

[The Night Stalker]

6 red days now

[The Night Stalker]

EPS 2.27 SO THAT is why it run to 3.84 on news, they run on milestones. start of phase 3, this bs offering gives me chance to buy. at lower prices. and in coming weeks, it goes again


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172003902

[The Night Stalker]

always sold at loss in the offerings and it runs big in coming weeks, trick is load up on dips and wait for it to unfold in coming weeks

[The Night Stalker]

https://stockcharts.com/h-sc/ui?s=drma&p=D&yr=0&mn=6&dy=0&id=p38090673899https://stockcharts.com/h-sc/ui?s=drma&p=D&yr=0&mn=6&dy=0&id=p38090673899

[The Night Stalker]

will double up here

[The Night Stalker]

https://www.otcmarkets.com/stock/DRMA/news/story?e&id=2524470

end of june

[The Night Stalker]

Dermata Therapeutics GAAP EPS of -$2.27
May 11, 2023 5:44 PM ETDermata Therapeutics, Inc. (DRMA)By: Gaurav Batavia, SA News Editor
Dermata Therapeutics press release (NASDAQ:DRMA): Q1 GAAP EPS of -$2.27.
As of March 31, 2023, Dermata had $8.8 million in cash and cash equivalents, compared to $6.2 million as of December 31, 2022.



https://seekingalpha.com/news/3970562-dermata-therapeutics-gaap-eps-of-2_27?utm_source=otcmarkets&utm_medium=referral

[The Night Stalker]

The gross proceeds to the Company from the registered direct offering and the concurrent private placement were approximately $1.8 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds for general corporate purposes, which includes, without limitation, ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to our technologies, licensing activities related to our current and future product candidates, and to the development of emerging technologies, investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses and working capital.

[sal32647]

https://finance.yahoo.com/news/dermata-therapeutics-announces-closing-1-200000286.html

A good read, Price should be much higher. In my opinion. Give it a little time.

[The Night Stalker]

the sky is falling

[The Night Stalker]

this dilution was uncalled for

[sal32647]

You hold and wait, you'll mise a good portion of the profit. imo.

[The Night Stalker]

Currently, Dermata has a Zacks Rank #3 (Hold).

Some better-ranked stocks for investors interested in the same sector are CRISPR Therapeutics CRSP, Kala Pharmaceuticals KALA and Allogene Therapeutics ALLO, each carrying a Zacks Rank #2 (Buy)

[The Night Stalker]

phase 2 topline results hence pop from .98 to 3.93. under 5m marketcap while its peers have large marketcaps, balance sheet looks good, this small offering dont scare me its not the end of world folks, will average down next week

[sal32647]

I think this one is a sleeper, When it wakes up this will be a good place to be. phase 3 begins, volume and price should pick up. IMO.

[The Night Stalker]

phase 3 trials start in june

[The Night Stalker]

those fucking offerings are strange, always sold. at loss. best to hold it out and wait

[sal32647]

This should be bottom. IMO.

[The Night Stalker]

they claimed the offering to raise 5m 2 months ago was able to fund operations into 2024, guess not.......


phase 3 trials start it pops

[The Night Stalker]

hit with fucking offering for 800k

[The Night Stalker]

hit with fucking offering for 800k

[The Night Stalker]

wrong ticker

[Invest-in-America]

DRMA: THANKS, Capt. N-S!!!

[The Night Stalker]

2.3m OS, topline results for phase 2, phase 3 in june, small offering in march to raise cash to fund operations till 2024

[The Night Stalker]

2.3m OS, topline results for phase 2, phase 3 in june, small offering in march to raise cash to fund operations till 2024

[The Night Stalker]

2.3m OS dated may 10 via 10q

nice 10q

[The Night Stalker]

may churn another week at best, but we will see large volume spikes and large price spikes in weeks ahead-

[The Night Stalker]

many biotechs are broke as fuck with those bs offerings, , we are funded till 2024


all its peers did homeruns

[The Night Stalker]

many biotechs are broke as fuck with those bs offerings, , we are funded till 2024


all its peers did homeruns

[Capitalvaluetrade]

Agreed, Good Post

[The Night Stalker]

same sector as KALA btw had a homerun pop

Currently, Dermata has a Zacks Rank #3 (Hold).

Some better-ranked stocks for investors interested in the same sector are CRISPR Therapeutics CRSP, Kala Pharmaceuticals KALA and Allogene Therapeutics ALLO, each carrying a Zacks Rank #2 (Buy) at present

[The Night Stalker]

did 1 to 3.93. tried again, this time we will break highs

[The Night Stalker]

offering for 5m was done in march to fund operations till 2024

im all about funding operations, topline clinical trials, market caps and Deadline for phase 3 in june

interesting volume on monthly chart


https://www.stockscores.com/charts/charts/?ticker=drma

[Capitalvaluetrade]

DRMA 6-Month Chart
https://www.barchart.com/stocks/quotes/DRMA/technical-chart?plot=BAR&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=DRMA&grid=1&height=500&studyheight=100

3-Month Chart
https://www.barchart.com/stocks/quotes/DRMA/technical-chart?plot=BAR&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=DRMA&grid=1&height=500&studyheight=100

1-Month Chart
https://www.barchart.com/stocks/quotes/DRMA/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=DRMA&grid=1&height=500&studyheight=100

[Capitalvaluetrade]

Excellent Chart, Early Beginnings of a Reversal Developed

[The Night Stalker]

basing well at much higher prices, with phase 3 trials starting in june, wants to break 3.80 one of these days

https://www.stockscores.com/charts/charts/?ticker=drma

[The Night Stalker]

https://www.stockscores.com/charts/charts/?ticker=drma

[Capitalvaluetrade]

Agreed, DRMA

[The Night Stalker]

basing well at these prices, phase 2 topline results, phase 3 in june

offering was done in march to fund operations until 2024

[The Night Stalker]

im not here to day trade it, higher lows. basing well here

[madras50]

sometimes this acts like it's gonna blow then backs off.

[The Night Stalker]

Currently, Dermata has a Zacks Rank #3 (Hold).

Some better-ranked stocks for investors interested in the same sector are CRISPR Therapeutics CRSP, Kala Pharmaceuticals KALA and Allogene Therapeutics ALLO, each carrying a Zacks Rank #2 (Buy) at presen